Physician profile
Erev E Tubb
NPI 1154429892
$2,360.25
in general payments reported to CMS, 2019-2025
30 companies · $1,336 in 2025
The $1,336 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.44 · 2020: $83.55 · 2021: $42.10 · 2022: $29.19 · 2023: $162 · 2024: $679 · 2025: $1,336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,176.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $549.02 | 2019-2025 | Opdualag, Augtyro, Krazati |
| Daiichi Sankyo INC. | $310.71 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Pfizer INC. | $213.32 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $135.23 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astellas Pharma US INC | $119.91 | 2024-2025 | Padcev, Xtandi |
| Celgene Corporation | $115.94 | 2023-2025 | Reblozyl, Pomalyst, Opdivo |
| Lilly USA, LLC | $94.68 | 2020-2025 | Verzenio, Jaypirca |
| Gilead Sciences, INC. | $86.90 | 2023-2025 | Trodelvy |
| Array Biopharma INC | $84.70 | 2024-2025 | Braftovi, Tukysa, Mektovi |
| Puma Biotechnology, INC. | $61.58 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $56.19 | 2025 | |
| Genentech USA, INC. | $53.52 | 2023-2024 | Tecentriq, Perjeta, Kadcyla |
| Jazz Pharmaceuticals INC. | $53.23 | 2024-2025 | |
| Eisai INC. | $49.22 | 2023-2025 | |
| Incyte Corporation | $46.77 | 2024-2025 | Jakafi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $33.63 | 2025 | Calquence, Lynparza |
| Cumberland Pharmaceuticals, INC. | $31.49 | 2025 | Sancuso |
| Janssen Biotech, INC. | $30.91 | 2023-2024 | Erleada, Darzalex |
| Abbvie INC. | $29.86 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $29.46 | 2020-2022 | |
| Genzyme Corporation | $27.15 | 2020-2021 | |
| Aveo Pharmaceuticals, INC. | $24.38 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.85 | 2025 | |
| Pharmacosmos Therapeutics INC. | $17.77 | 2025 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $17.68 | 2025 | Ninlaro |
| Taiho Oncology, INC. | $16.67 | 2023 | |
| Geron Corporation | $16.59 | 2025 | Rytelo |
| Azurity Pharmaceuticals, INC. | $16.32 | 2025 | Danziten |
| Alexion Pharmaceuticals, INC. | $15.57 | 2024 | Ultomiris |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erev Tubb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.